Combination therapy

Details Combination therapy Combination therapy

A - Human Necessities

61

K

A61K 38/55 (2006.01) A61K 31/00 (2006.01) A61K 31/155 (2006.01) A61K 31/336 (2006.01) A61K 31/415 (2006.01) A61K 31/4192 (2006.01) A61K 31/437 (2006.01) A61K 31/4709 (2006.01) A61K 31/4725 (2006.01) A61K 31/4745 (2006.01) A61K 31/495 (2006.01) A61K 31/5025 (2006.01) A61K 31/5513 (2006.01) A61K 45/06 (2006.01) A61K 45/08 (2006.01) A61P 9/10 (2006.01)

Patent

CA 2369212

Disclosed is a pharmaceutical composition for reducing tissue damage in a mammal resulting from ischemia, which comprises a combination of a sodium/hydrogen exchange type-1 (NHE-1) inhibitor and a second compound selected from the group consisting of: (a) a complement modulator, (b) a metabolic modulator, (c) an anti-apoptotic agent, (d) a nitric oxide synthase-related agent, (e) an enzyme/protein modulator, and an enzyme/protein modulator selected from the group consisting of a protein kinase C activator, an endothelia converting enzyme inhibitor, a tissue-activated fibrinolytic inhibitor (TAFI), a Na+/Ca+2 exchanger isoform-1 (NCX-1) inhibitor, and a poly (ADP ribose) synthetase (PARS/PARP) inhibitor; and, preferably, a pharmaceutically acceptable carrier, vehicle, or diluent. Further disclosed is a kit comprising an amount of the NHE-1 inhibitor, and a pharmaceutically acceptable carrier, vehicle, or diluent in a first unit dosage form; an amount of the second compound, and a pharmaceutically acceptable carrier, vehicle, or diluent in a second unit dosage form; and a container.

Affiliated with

Also associated with

Rating

Combination therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1378769